World Novelty: Artificial HPL Solution

First Artificial Human Platelet Lysate

BioScience Raises the Bar in Cell Culture Technology with artificial HPL

PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. In partnership with the Korean biotech DewCell Biotherapeutics, PL BioScience has developed the proprietary method to transform lab-grown platelets into a powerful cell culture supplement. DewCell is the the first company to generate artificial platelets from stem cells in a reactor.

Produced in Germany with raw material from DewCell, this new technology offers a scalable, safe, and animal-free alternative to Fetal Bovine Serum (FBS) and conventional HPL. Recently, PL BioScience filed a patent for the process.

“Cell culture innovation is crucial for advancing modern medicine, drug discovery, and, ultimately, understanding complex biological systems,” said Dr. Hatim Hemeda, Chief Executive Officer of PL BioScience. “Thus, we are proud to contribute to the field with the very first, scalable artificial HPL solution. In the mid-term, our solution can be produced in a nearly unlimited supply. In an effort to meet the growing biopharmaceutical industry needs.”

“We are confident that the combination of DewCell’s innovative technology and our cell culture expertise will usher in a new era in the field of regenerative medicine and cell therapy manufacturing,” he added.

Read the full press release here.